Caplin Point Laboratories' Q1 FY 2026-27 Quarterly Results

Result Summary

• Caplin Point Laboratories Ltd reported a 2.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 20.7%.
• Its expenses for the quarter were up by 0.9% QoQ and 20.0% YoY.
• The net profit increased 3.6% QoQ and increased 18.8% YoY.
• The earnings per share (EPS) of Caplin Point Laboratories Ltd stood at 23.21 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Caplin Point Laboratories Ltd is a pharmaceutical company, primarily engaged in the development, manufacture, and marketing of pharmaceutical products. The company operates in the healthcare and pharmaceutical industry, focusing on producing a range of formulations, including analgesics, anti-infectives, and anti-diabetic medications. Caplin Point Laboratories is known for its strong presence in emerging markets, particularly in Latin America and Africa. The company continues to expand its product portfolio and geographical reach, capitalizing on opportunities in the pharmaceutical sector. Recent data points to steady growth in its financial performance, reflecting its strategic focus and operational efficiency. Specific recent developments or strategic initiatives beyond this scope are not available in the provided data.

Revenue

For the first quarter of fiscal year 2027 (Q1FY27), Caplin Point Laboratories Ltd reported a total income of ₹643.91 crores. This represents a 2.4% increase from the preceding quarter (Q4FY26), where the total income was ₹628.52 crores. Compared to the same quarter in the previous fiscal year (Q1FY26), where the total income was ₹533.36 crores, this marks a year-over-year (YoY) increase of 20.7%. The consistent growth in revenue over these periods demonstrates the company's robust sales performance and ability to scale its operations effectively. Revenue growth is a critical indicator of the company's market demand and its ability to leverage its product offerings.

Profitability

Caplin Point Laboratories Ltd's profitability metrics indicate a solid financial performance in Q1FY27. The company's profit before tax (PBT) for the quarter was ₹225.23 crores, which is a 5.5% increase from the previous quarter's PBT of ₹213.44 crores. On a YoY basis, the PBT rose by 22.1% from ₹184.43 crores in Q1FY26. After accounting for taxes, the profit after tax (PAT) for Q1FY27 stood at ₹179.09 crores, reflecting a 3.6% increase from Q4FY26's PAT of ₹172.88 crores and an 18.8% rise from ₹150.76 crores in Q1FY26. These figures highlight the company's ability to maintain cost efficiency and profitability amidst its revenue growth. The tax expense for Q1FY27 was ₹46.13 crores, up 13.7% QoQ and 36.9% YoY, indicating an increase in tax liabilities concurrent with rising profits.

Operating Metrics

In terms of operating metrics, Caplin Point Laboratories Ltd experienced stable cost management, with total expenses in Q1FY27 recorded at ₹418.68 crores, a slight increase of 0.9% from ₹415.08 crores in Q4FY26. Year-over-year, the total expenses saw a 20.0% rise from ₹348.93 crores in Q1FY26. The Earnings Per Share (EPS) for Q1FY27 was ₹23.21, reflecting a 4.0% increase from the previous quarter's EPS of ₹22.31, and a 15.9% rise from ₹20.03 in Q1FY26. These operating metrics suggest a balanced approach to managing operational costs while enhancing shareholder value through improved earnings per share. The trends in expenses and EPS provide insight into the company's operational efficiency and its success in delivering value to its stakeholders.